PGxAI Debuts Vega, an AI Model Set to Disrupt Precision Medicine

PALO ALTO, Calif., Feb. 18, 2025 — PGxAI, a leader in AI-driven pharmacogenetics, has introduced Vega, its latest artificial intelligence model designed to help physicians and health systems tailor drug therapy to individual genetic profiles. By analyzing genetic data alongside clinical guidelines, Vega aims to improve treatment outcomes and reduce adverse drug reactions—one of the leading causes of mortality worldwide.

Vega expands PGxAI’s platform, covering more than 1,200 drugs and 350 genes—seventy times the scope of traditional pharmacogenetic panels, an advancement made possible only by Vega’s foundational GenAI model.

“Vega empowers clinical pharmacists and physicians to provide ultra-precise recommendations,” said Dr. Mike Zack, PGxAI co-founder and CEO. “Think of it as an AI-driven clinical partner that leverages genomics and next-generation AI to refine therapeutic decisions. By automating complex pharmacogenetic analysis, Vega frees healthcare professionals to focus on patient care while ensuring they have the latest clinical evidence at their fingertips.”

Traditionally, developing medication guidance required months of manual analysis. Vega generates those insights in minutes, accelerating the shift toward truly personalized medicine.

“Vega enables physicians and health systems to mitigate adverse drug reactions, moving us closer to a world where pharmacogenetics is a routine part of clinical care,” said Allan Gobbs, PGxAI co-founder and executive chairman.“This model is a foundational step toward integrating additional omics layers and real-world clinical outcomes. Future iterations will seamlessly incorporate emerging biomarker data and broader clinical evidence.”

Vega builds on PGxAI’s previous model, Sirius, which focused on risk classification by identifying patients prone to adverse drug reactions. The new model takes the next step—interpreting clinical guidelines and instantly generating treatment recommendations tailored to a patient’s genetic profile.

Vega is bolstered by PGxAI’s partnerships with industry leaders such as Nvidia, InterSystems, Google, and Microsoft. InterSystems’ HealthShare platform plays a key role in integrating Vega with healthcare IT systems, facilitating real-time data exchange and seamless clinical implementation.

Vega advances PGxAI’s goal of expanding pharmacogenetic coverage to 21,000 therapeutic substances by 2027, automating the creation of gene-based medication guidelines at scale.

PGxAI is backed by ATEM Capital, a New York-based venture capital firm specializing in life sciences innovation.

About PGxAI

Founded in 2023, Palo Alto-based PGxAI is at the forefront of AI-powered pharmacogenetics, using real-world data to drive advancements in precision medicine. The platform’s proprietary AI models personalize drug selection, dosage, and interaction management. PGxAI’s leadership includes Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert and CEO & Co-Founder, and Allan Gobbs, a life sciences venture capitalist and the company’s Executive Chairman. Its Advisory Board features Dr. Russ Altman of Stanford University and executives from Thermo Fisher, GE Healthcare, and other leading organizations. Strategically partnered with InterSystems and backed by ATEM Capital, PGxAI is addressing the critical need for personalized, data-driven therapies and setting new standards in precision medicine.